Testing a new medication to help control seizures in Dravet syndrome

This trial is testing clemizole hydrochloride as an add-on treatment for people with Dravet syndrome whose seizures aren't fully controlled by their current medications. About 150 people will participate in this study, which lasts 20 weeks, to see if this medication is safe and whether it helps reduce how often seizures happen. Half of participants will receive the new medication, and half will receive a placebo (a pill with no active medicine) so researchers can fairly compare the results.

Dravet syndrome is a severe form of epilepsy that begins in infancy and can be very difficult to treat with existing anti-seizure medications. This trial exists because many people with Dravet syndrome continue to have breakthrough seizures even while taking multiple drugs, and researchers want to find new treatment options that could help reduce these dangerous seizures.